PCH
CBAY

Polar Capital Holdings’s Cymabay Therapeutics CBAY Stock Holding History

Polar Capital Holdings’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-81,630
Closed -$298 – 471
2021
Q3 		$298 Hold
81,630
– – ﹤0.01% 346
2021
Q2 		$356 Buy
81,630
+25,000
+44% +$111K ﹤0.01% 344
2021
Q1 		$257K Buy
+56,630
New +$305K ﹤0.01% 317

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Polar Capital Holdings's CBAY Position: Q4 2021 in Review

Polar Capital Holdings sold out of Cymabay Therapeutics (CBAY) in Q4 2021, closing a stake of 81,630 shares — an estimated $298 sold.

Polar Capital Holdings first reported a position in CBAY in Q1 2021 and held it in 3 quarters. The position peaked at $257K in Q1 2021. 113 funds tracked by Wall St. Rank hold CBAY as of Q4 2021.

  • Polar Capital Holdings reported no remaining Cymabay Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Polar Capital Holdings sold 81,630 Cymabay Therapeutics shares in Q4 2021, an estimated $298.
  • Polar Capital Holdings first reported a position in Cymabay Therapeutics in Q1 2021 and held it in 3 quarters.
  • Polar Capital Holdings's Cymabay Therapeutics position peaked at $257K in Q1 2021.
  • 113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2021.

Based on Polar Capital Holdings's 13F filing for Q4 2021, filed 14 Feb 2022.